Research doesn't always move as fast as you'd like, but sometimes innovations come when and where you least expect them.

A development-stage pharma company called Medivation is holding clinical trials of a new drug called MDV3100. The drug is intended for prostate cancer, but what's interesting to us is the drug fights prostate cancer by blocking the androgen receptor (AR) and also slowing the translocation of the AR to the nucleus of the cell. Following quote is from Wikipedia:

"MDV3100 has approximately fivefold higher binding affinity for the androgen receptor (AR) compared to the antiandrogen bicalutamide...As opposed to bicalutamide, MDV3100 does not promote translocation of AR to the nucleus and in addition prevents binding of AR to DNA and AR to coactivator proteins."

Full article at this link; or just search on Google, and several articles on MDV3100 can be found.